BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38273803)

  • 1. Patient survey on cancer genomic medicine in Japan under the national health insurance system.
    Kage H; Akiyama N; Chang H; Shinozaki-Ushiku A; Ka M; Kawata J; Muto M; Okuma Y; Okita N; Tsuchihara K; Kikuchi J; Shirota H; Hayashi H; Kokuryo T; Yachida S; Hirasawa A; Kubo M; Kenmotsu H; Tanabe M; Ushiku T; Muto K; Seto Y; Oda K
    Cancer Sci; 2024 Mar; 115(3):954-962. PubMed ID: 38273803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan.
    Kohno T; Kato M; Kohsaka S; Sudo T; Tamai I; Shiraishi Y; Okuma Y; Ogasawara D; Suzuki T; Yoshida T; Mano H
    Cancer Discov; 2022 Nov; 12(11):2509-2515. PubMed ID: 36321305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan.
    Sunami K; Naito Y; Aimono E; Amano T; Ennishi D; Kage H; Kanai M; Komine K; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Yoshino T
    Int J Clin Oncol; 2021 Mar; 26(3):443-449. PubMed ID: 33385275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study.
    Matsuoka A; Fujimori M; Koyama T; Sato A; Mori K; Hirata M; Tanabe N; Nakachi K; Kato S; Okamoto H; Ogawa K; Komatsu H; Iwasaku M; Miyaji T; Uchitomi Y
    BMJ Open; 2023 Nov; 13(11):e072472. PubMed ID: 37996226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan.
    Kanai M
    Curr Oncol; 2022 Sep; 29(10):7272-7284. PubMed ID: 36290850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Precision Medicine Provided by National Health Insurance].
    Muto M; Kondo T; Matsubara J; Kanai M; Matsumoto S; Ashida K; Suga J; Mukai K
    Gan To Kagaku Ryoho; 2020 Aug; 47(8):1158-1163. PubMed ID: 32829347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Additional Remarks on the Issue of Cancer Genomic Medicine-Focusing on Medical Insurance Issues].
    Nishihara H
    Gan To Kagaku Ryoho; 2022 Sep; 49(9):1011-1013. PubMed ID: 36156029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronological improvement in precision oncology implementation in Japan.
    Sunami K; Naito Y; Komine K; Amano T; Ennishi D; Imai M; Kage H; Kanai M; Kenmotsu H; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Saigusa Y; Yoshino T
    Cancer Sci; 2022 Nov; 113(11):3995-4000. PubMed ID: 35976133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan.
    Kage H; Oda K; Muto M; Tsuchihara K; Okita N; Okuma Y; Kikuchi J; Shirota H; Hayashi H; Kokuryo T; Sakai D; Hirasawa A; Kubo M; Kenmotsu H; Akiyama N; Shinozaki-Ushiku A; Tanabe M; Ushiku T; Miyagawa K; Seto Y
    Cancer Sci; 2023 Jul; 114(7):3041-3049. PubMed ID: 37165760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Questionnaire Survey on the Timing of Comprehensive Genomic Profiling for Advanced Recurrent Colorectal Cancer and Its Impact on Patients].
    Yarimizu A; Kuribayashi M; Nomura K; Kimura K; Takenaka Y; Song J; Ohashi E; Nishimura Y; Demachi T; Hirata M; Beppu N; Uchino M; Ikeuchi H; Ikeda M; Kataoka K
    Gan To Kagaku Ryoho; 2023 Aug; 50(8):891-893. PubMed ID: 37608415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Challenges in Expert Panel].
    Yachida S
    Gan To Kagaku Ryoho; 2022 Sep; 49(9):994-996. PubMed ID: 36156023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience.
    Ohtsu A; Goto K; Yoshino T
    Proc Jpn Acad Ser B Phys Biol Sci; 2023 Oct; 99(8):241-253. PubMed ID: 37558430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
    Kikuchi J; Ohhara Y; Takada K; Tanabe H; Hatanaka K; Amano T; C Hatanaka K; Hatanaka Y; Mitamura T; Kato M; Shibata Y; Yabe I; Endoh A; Komatsu Y; Matsuno Y; Sugiyama M; Manabe A; Sakurai A; Takahashi M; Naruse H; Torimoto Y; Dosaka-Akita H; Kinoshita I
    Jpn J Clin Oncol; 2021 Apr; 51(5):753-761. PubMed ID: 33532831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
    Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
    Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
    Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
    J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Panel Discussion - Problems in the Cancer Genomic Medicine].
    Ishioka C; Muto M; Yachida S; Shirota H; Hirasawa A; Miyagawa K; Ashizawa K; Kinoshita I; Nishihara H; Matsuura N; Sakurai A
    Gan To Kagaku Ryoho; 2022 Sep; 49(9):1014-1017. PubMed ID: 36156030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan.
    Kage H; Shinozaki-Ushiku A; Ishigaki K; Sato Y; Tanabe M; Tanaka S; Tanikawa M; Watanabe K; Kato S; Akagi K; Uchino K; Mitani K; Takahashi S; Miura Y; Ikeda S; Kojima Y; Watanabe K; Mochizuki H; Yamaguchi H; Kawazoe Y; Kashiwabara K; Kohsaka S; Tatsuno K; Ushiku T; Ohe K; Yatomi Y; Seto Y; Aburatani H; Mano H; Miyagawa K; Oda K
    Cancer Sci; 2023 Apr; 114(4):1710-1717. PubMed ID: 36601953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey.
    Minamoto A; Yamada T; Shimada S; Kinoshita I; Aoki Y; Oda K; Ueki A; Higashigawa S; Morikawa M; Sato Y; Hirasawa A; Ogawa M; Kondo T; Yoshioka M; Kanai M; Muto M; Kosugi S
    J Hum Genet; 2022 Oct; 67(10):557-563. PubMed ID: 35322199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and implementation of Cancer Genomic Medicine in Japan.
    Mukai Y; Ueno H
    Cancer Sci; 2021 Mar; 112(3):970-977. PubMed ID: 33289217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current Status and Future Direction of Cancer Genomic Medicine in Japan].
    Muto M
    Gan To Kagaku Ryoho; 2020 Feb; 47(2):197-202. PubMed ID: 32381946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.